Erasca Inc (ERAS) - News Archive

Erasca, a leading biopharmaceutical company, has recently commenced the SEACRAFT-2 pivotal Phase 3 trial to assess the efficacy and safety of a potential breakthrough treatment for NRAS-mutant melanoma. The combination...

SAN DIEGO, May 21, 2024 Erasca Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company specializing in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, h...

In the rapidly evolving field of cancer research, Erasca has recently made groundbreaking strides with their strategic in-licensing of a RAS-targeting franchise, featuring the remarkable Pan-RAS molecular glue ERAS-0015...

Erasca, Inc. Secures $160 Million in Underwritten Offering to Advance Precision Oncology TherapiesSAN DIEGO, May 16, 2024 - Erasca, Inc. (Nasdaq: ERAS), a leading clinical-stage precision oncology company specializing i...

1. Funding Extends Erasca s Cash Runway as Company Records Net LossErasca Inc, a leading biotechnology company focused on developing precision oncology therapies, has recently announced an extension of its anticipated c...

In the quest for more effective treatments for RAS/MAPK pathway-driven tumors, Erasca Pharmaceuticals has announced two groundbreaking clinical trial collaboration and supply agreements for the evaluation of trametinib...

Erasca Receives FDA Fast Track Designation for Promising Pan-RAF Inhibitor in NRAS-Mutated MelanomaErasca, a leading biopharmaceutical company, recently announced that its novel Pan-RAF inhibitor, Naporafenib, has been...

Erasca s Groundbreaking Achievements in Naporafenib and ERAS-801 Programs Pave the Way for Innovation and Extended Cash RunwayGained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design f...